Uterine Cancer Therapeutics & Diagnostics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer Type (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma), By Therapeutics (Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, others), By Diagnostics (Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage, CT scan), By Region, and Competition, 2020-2030F

Market Overview

Global Uterine Cancer Therapeutics & Diagnostics Market was valued at USD 23.10 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.75% through 2030. Uterine cancer, also known as endometrial cancer, is a type of cancer that originates in the lining of the uterus, called the endometrium. The uterus is a female reproductive organ where a fertilized egg implants and a developing fetus grows during pregnancy. Uterine cancer occurs when there is uncontrolled growth of abnormal cells within the endometrial lining. Uterine cancer often presents with symptoms such as abnormal vaginal bleeding, pelvic pain, and changes in urinary or bowel habits. The risk factors for uterine cancer include obesity, hormone imbalances, a family history of the disease, and certain genetic conditions like Lynch syndrome. Diagnosis of uterine cancer typically involves a combination of medical history evaluation, physical examination, imaging studies (such as transvaginal ultrasound, MRI, or CT scans), and tissue biopsy (usually obtained through endometrial biopsy or dilation and curettage). Staging of the cancer helps determine the extent of its spread and guides treatment decisions. Treatment for uterine cancer varies depending on the stage, type, and individual patient factors but often includes surgery (such as hysterectomy), radiation therapy, chemotherapy, targeted therapy, and, in some cases, immunotherapy. Early detection and timely treatment can lead to favorable outcomes for many uterine cancer patients. Improved diagnostic techniques, including imaging modalities like MRI and CT scans, as well as molecular and genetic testing, enabled earlier and more accurate diagnosis of uterine cancer. Ongoing research and development efforts led to innovations in uterine cancer therapeutics. This included the development of targeted therapies, immunotherapies, and novel chemotherapeutic agents. The aging population, particularly in developed nations, contributed to a higher prevalence of uterine cancer. Older individuals are at higher risk for this type of cancer.

Key Market Drivers

Rising Geriatric Population

The rising geriatric population is a key driver fueling the growth of the global uterine cancer therapeutics & diagnostics market. The global population aged 65 and older is expected to more than double, increasing from 761 million in 2021 to 1.6 billion by 2050. The 80+ demographic is expanding at an even faster rate. This irreversible demographic shift is set to reshape industries, drive demand for age-specific healthcare solutions, and create new market opportunities across pharmaceuticals, medical diagnostics, elderly care services, and insurance sectors.  As the global population ages, the prevalence of uterine cancer—particularly endometrial cancer—has increased, leading to a higher demand for advanced diagnostics, innovative treatments, and specialized healthcare services. Below is a detailed analysis of how the aging demographic is shaping this market. Uterine cancer is more common among postmenopausal women, with the majority of cases diagnosed in women aged 50 and above. Endometrial cancer (EC) ranks as the sixth most prevalent cancer among women globally, with its incidence surging significantly over the past two decades. In 2019 alone, 435,041 new cases were diagnosed, resulting in 91,641 fatalities worldwide. This sharp rise underscores the growing burden on healthcare systems, accelerating demand for advanced diagnostics, targeted therapies, and innovative treatment solutions in the oncology market. As global life expectancy increases, the number of elderly women at risk also grows, leading to a direct rise in demand for cancer diagnostics and therapeutics. With an aging population, healthcare providers are prioritizing early detection and preventive screening programs to manage uterine cancer effectively. Governments and healthcare organizations are actively investing in: Routine gynecological screenings for older women, Biomarker-based diagnostic tests to detect cancer in early stages, AI-driven imaging solutions (MRI, PET scans) for precise detection. This increasing emphasis on early diagnosis and regular screenings is driving the market for diagnostic devices, pathology services, and molecular testing kits.

In 2014, healthcare utilization by Malaysia’s elderly population incurred an estimated RM 3.8 billion, accounting for 0.34% of the national GDP and 8% of total healthcare expenditure. By 2040, this economic burden is projected to skyrocket to RM 21 billion, representing 1.08% of GDP. As Malaysia transitions into an aged nation by 2045, escalating healthcare costs will drive demand for specialized geriatric care, advanced medical technologies, and sustainable healthcare financing solutions, presenting both challenges and opportunities for the industry. Older populations tend to spend more on healthcare, cancer treatments, and specialized care due to the increased incidence of chronic diseases, including uterine cancer. This higher healthcare expenditure is translating into: Increased adoption of advanced therapies, such as targeted therapy and immunotherapy, Growing utilization of minimally invasive and robotic-assisted surgeries for uterine cancer treatment, Expansion of palliative care services for elderly cancer patients. With more resources being allocated to geriatric oncology, pharmaceutical and biotech companies are expanding their portfolios to cater to age-specific treatment needs.

Rising Prevalence of Uterine Cancer

The increasing prevalence of uterine cancer, particularly endometrial cancer, is a significant market driver propelling the growth of the global uterine cancer therapeutics & diagnostics market. In the United States, endometrial cancer remains the most prevalent malignancy affecting the female reproductive system. According to the American Cancer Society’s 2025 projections, an estimated 69,120 new cases will be diagnosed, with 13,860 fatalities expected. The rising incidence highlights a growing market demand for advanced diagnostics, innovative treatment options, and targeted therapeutics, reinforcing the need for investment in oncology research and healthcare infrastructure. As incidence rates rise worldwide, there is a growing demand for early detection, innovative treatment solutions, and advanced healthcare infrastructure. Uterine cancer is one of the most common gynecological malignancies, with a growing number of cases reported annually. According to global health organizations, factors such as changing lifestyles, obesity, diabetes, hormonal imbalances, and prolonged estrogen exposure have contributed to the surge in cases. This rising prevalence is driving the demand for early-stage diagnostic tools, advanced imaging technologies, and biomarker-based tests to improve detection rates. Expansion of molecular diagnostics, liquid biopsy, and imaging technologies, Increased adoption of AI-powered screening tools for early detection, Rising investment in oncology-focused laboratory testing services. As a result, diagnostic device manufacturers, biotech firms, and pathology service providers are witnessing significant revenue growth.

With an increasing number of uterine cancer cases, there is a shift from traditional treatments (surgery, radiation, chemotherapy) to targeted therapies and immunotherapy-based treatments. Advances in genomic research and precision medicine have led to the development of drugs tailored to individual patient profiles, improving treatment efficacy. Rising demand for immune checkpoint inhibitors (e.g., pembrolizumab, dostarlimab), Growth in targeted therapies such as PI3K/mTOR inhibitors, Increased adoption of minimally invasive and robotic-assisted surgeries This trend is fueling pharmaceutical and biotech investments in research & development, expanding the market for next-generation cancer therapeutics.

Download Free Sample Report

Key Market Challenges

Comorbidities and Multidisciplinary Care

Many uterine cancer patients have comorbid conditions, such as diabetes, hypertension, heart disease, or obesity. Managing uterine cancer alongside these comorbidities can complicate treatment decisions. Healthcare providers must weigh the benefits of aggressive cancer treatment against the potential risks and interactions with existing health conditions and medications. Comorbidities can affect a patient's ability to tolerate cancer treatments, such as surgery, chemotherapy, or radiation therapy. For example, individuals with heart disease may be at increased risk during surgery or may not tolerate certain chemotherapy regimens. Patients with multiple health conditions often take multiple medications. The potential for drug interactions between cancer therapies and medications for comorbidities must be carefully managed to avoid adverse effects. Due to the complexity of managing uterine cancer in patients with comorbidities, a multidisciplinary approach involving oncologists, surgeons, cardiologists, endocrinologists, and other specialists is often necessary. Coordinating care and communication among these specialists can be challenging. Each patient's case is unique, requiring individualized treatment plans that consider both the cancer and comorbidities. This necessitates close collaboration among healthcare providers. Determining the optimal sequencing of cancer treatments and interventions for comorbidities is crucial. For example, deciding whether to address heart disease or uterine cancer first can impact treatment outcomes.

Cost of Treatment

Uterine cancer treatment often involves a combination of modalities, including surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Each of these treatments comes with its own costs, and the total expense can be substantial. Advancements in cancer therapies, such as targeted therapies and immunotherapies, tend to be expensive. These treatments are often tailored to individual patients and can be cost-prohibitive for some. Diagnostic tests and imaging, including MRI, CT scans, PET scans, and genetic profiling, can be expensive. Multiple diagnostic tests may be needed for accurate staging and treatment planning. Chemotherapy drugs, immunotherapy drugs, and targeted therapies can be costly. Some patients require these medications over an extended period, which can result in significant expenses. Surgical procedures, including minimally invasive and robotic-assisted surgeries, can be expensive, especially if complications arise. The need for a multidisciplinary care team involving oncologists, surgeons, radiologists, and other specialists can lead to increased consultation and treatment costs. Managing side effects of treatment, such as nausea, anemia, and fatigue, often requires additional medications and medical interventions.

Key Market Trends

Precision Medicine

Advances in genetic testing allowed for the comprehensive profiling of uterine cancer tumors. This profiling identified specific genetic mutations and alterations that drive cancer growth. Oncologists could use this information to select targeted therapies that were more likely to be effective for individual patients. Researchers were identifying and validating specific biomarkers associated with uterine cancer. These biomarkers could be used for early detection, prognosis assessment, and treatment decision-making. Precision medicine guided treatment decisions based on the molecular characteristics of a patient's tumor. This approach minimized the use of one-size-fits-all treatments and aimed to improve treatment efficacy while reducing side effects. Immunotherapy drugs, which stimulate the patient's immune system to target cancer cells, were being explored as part of precision medicine approaches for uterine cancer. Some patients with specific molecular profiles responded well to immunotherapy. Precision medicine was driving the design of clinical trials that focused on specific genetic subtypes of uterine cancer. These trials aimed to test new therapies and treatment combinations tailored to the molecular profiles of patients. Precision medicine also played a role in assessing a patient's risk of developing uterine cancer based on their genetic and environmental factors. This could inform prevention and early detection strategies.

Segmental Insights

Cancer Type Insights

In 2024, the endometrial adenocarcinoma segment is emerging as the fastest-growing category based on cancer type. This rapid expansion is driven by rising incidence rates, advancements in precision medicine, growing adoption of targeted therapies, and increasing healthcare investments.  Endometrial adenocarcinoma is the most common type of uterine cancer, accounting for a substantial portion of uterine cancer cases. This high incidence can lead to a greater emphasis on research, diagnostics, and therapeutics specific to this subtype. Endometrial adenocarcinoma has distinct molecular and histological characteristics that may require tailored treatment approaches. Understanding these specific characteristics is essential for developing effective therapies and diagnostics. Early detection is critical for improving the prognosis of uterine cancer, and endometrial adenocarcinoma is often diagnosed at an earlier stage compared to other subtypes. This may result in a greater focus on screening and diagnostics for this subtype. Clinical trials and research efforts often focus on specific cancer subtypes, including endometrial adenocarcinoma. Advances in treatment options, including targeted therapies and immunotherapies, may have been more prominent in this segment.

Therapeutics Insights

In 2024, the Global Uterine Cancer Therapeutics & Diagnostics Market by chemotherapy segment and is predicted to continue expanding over the coming years.  Chemotherapy has long been a standard treatment for uterine cancer, especially for patients with advanced or recurrent disease. It is often used in combination with surgery or radiation therapy to improve treatment outcomes. Chemotherapy can be used in various stages of uterine cancer, from early-stage to advanced-stage disease. This versatility makes it a commonly prescribed treatment option. In some cases, chemotherapy is combined with other treatments, such as radiation therapy or targeted therapy, to enhance the overall effectiveness of treatment. Uterine cancer can spread beyond the uterus, making it necessary to target cancer cells that may have travelled to other parts of the body. Chemotherapy is a systemic treatment that can reach cancer cells throughout the body.

Download Free Sample Report

Regional Insights

The North America region was the largest market in the Global Uterine Cancer Therapeutics & Diagnostics Market in 2024. North America, particularly the United States, has one of the highest healthcare spending rates in the world. This substantial investment in healthcare infrastructure and research and development contributes to advancements in uterine cancer therapeutics and diagnostics. The region boasts advanced healthcare facilities, medical technology, and a well-developed healthcare system. This allows for early detection, accurate diagnosis, and state-of-the-art treatment options for uterine cancer patients. North America is home to numerous pharmaceutical and biotechnology companies that invest heavily in cancer research, including uterine cancer. These companies develop innovative therapeutics and diagnostic tools for the market. The United States hosts a large number of clinical trials for various cancer types, including uterine cancer. Clinical trials are critical for testing new treatments and diagnostic methods, attracting patients from around the world.

Recent Developments

• In August 2024, The U.S. Food and Drug Administration (FDA) has granted approval for dostarlimab-gxly (Jemperli, GSK) in combination with carboplatin and paclitaxel, followed by dostarlimab-gxly as a monotherapy, for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC). Previously, this regimen was approved specifically for cases of primary advanced or recurrent EC characterized by mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). This expanded approval broadens treatment access, reinforcing dostarlimab-gxly’s role in the evolving standard of care for endometrial cancer and driving further adoption of immunotherapy-based treatment strategies in oncology.
• In June 2024, Merck, announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, the company’s anti-PD-1 therapy, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a monotherapy, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. This latest approval represents KEYTRUDA’s third indication for endometrial carcinoma and its 40th overall FDA-approved indication in the U.S., further reinforcing its expanding role in oncology treatment protocols and increasing market penetration in the gynecologic cancer segment.
• In June 2023, A PCR-based endometrial cancer detection test was introduced by Singapore company Inex Innovate. With more than 400,000 newly diagnosed cases and about 100,000 annual deaths, endometrial cancer is the most prevalent gynecological malignancy. An enlarged uterus, irregular vaginal bleeding after menopause, and pelvic pain are typical symptoms.
• In March 2023, The Cancer Awareness Prevention and Early Detection Trust (CAPED), a non-profit organization devoted to promoting cancer awareness, prevention, and early detection, and Roche Diagnostics India announced the signing of a Memorandum of Understanding (MoU). The two groups will work together to fight cervical cancer, which is the second most frequent malignancy among Indian women, according to the MoU. The collaboration with CAPED is a component of Roche's larger dedication to enhancing cancer treatment across the world. The business has a long history of innovation in cancer medicines and diagnostics and has been at the forefront of creating fresh methods for treating the disease.

Key Market Players

• Ariad Pharmaceuticals, Inc.
• Abbott Laboratories Inc.
• Becton, Dickinson & Co.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Novartis AG
• Sanofi SA
• Siemens Healthineers AG.
• F. Hoffmann-La Roche AG

Report Scope:

In this report, the Global Uterine Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

•  Uterine Cancer Therapeutics & Diagnostics Market, By Cancer Type:

o   Endometrial Adenocarcinoma

o   Adenosquamous Carcinoma

o   Papillary Serous Carcinoma

o   Uterine Sarcoma

•  Uterine Cancer Therapeutics & Diagnostics Market, By Therapeutics:

o   Surgery

o   Immunotherapy

o   Radiation Therapy

o   Chemotherapy

o   Others

•  Uterine Cancer Therapeutics & Diagnostics Market, By Diagnostics:

o   Biopsy

o   Pelvic Ultrasound

o   Hysteroscopy

o   Dilation and Curettage

o   CT scan

• Uterine Cancer Therapeutics & Diagnostics Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Uterine Cancer Therapeutics & Diagnostics Market.

Available Customizations:

Global Uterine Cancer Therapeutics & Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Uterine Cancer Therapeutics & Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com